Physician profile
Sol Reisin
NPI 1700844222
$229.22
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.73 | 2019 | |
| Amarin Pharma, INC. | $39.11 | 2019 | |
| Sunovion Pharmaceuticals INC. | $27.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.63 | 2019 | |
| Akebia Therapeutics INC | $18.71 | 2019 | |
| Merck Sharp & Dohme LLC | $18.34 | 2019 | |
| Lilly USA, LLC | $17.16 | 2019 | |
| Bioventus LLC | $14.47 | 2019 | |
| Novo Nordisk INC | $14.05 | 2019 | |
| Glaxosmithkline, LLC. | $12.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sol Reisin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.